Table 2 The association between LINE-1 methylation status and clinical variables of the study population (stage III and high-risk stage II CRCs)
Parameters | LINE-1 methylation levels (low vs. high)a | |||||
|---|---|---|---|---|---|---|
Cancer sample (n = 336) | Normal lymph node sample (n = 336) | |||||
OR | (95Â % C.I.) | P b | OR | (95Â % C.I.) | P b | |
Gender | ||||||
 (Male vs. female) | 1.49 | (0.921–2.406) | 0.104 | 1.06 | (0.670–1.677) | 0.803 |
Age | ||||||
 (≥60 years vs. <60 years) | 1.20 | (0.752–1.899) | 0.450 | 0.95 | (0.611–1.480) | 0.823 |
BMI | ||||||
 (Overweight vs. normal) | 1.24 | (0.775–1.996) | 0.366 | 1.76 | (1.118–2.765) | 0.015 |
Tumor location | ||||||
 (Distal vs. proximal) | 0.81 | (0.474–1.373) | 0.429 | 1.26 | (0.762–2.079) | 0.370 |
Pathology | ||||||
 (Mucinous vs. non-mucinous) | 0.83 | (0.196–3.521) | 0.802 | 1.44 | (0.349–5.926) | 0.616 |
Differentiation | ||||||
 (High grade vs. low grade) | 0.37 | (0.111–1.211) | 0.100 | 0.68 | (0.213–2.173) | 0.515 |
T stage | ||||||
 (T4 vs. T1, 2, 3) | 0.81 | (0.403–1.629) | 0.555 | 0.68 | (0.347–1.324) | 0.255 |
N stage | ||||||
 (N2 vs. N 0, 1) | 1.24 | (0.715–2.156) | 0.443 | 1.15 | (0.681–1.938) | 0.602 |
Microsatellite status | ||||||
 (MSI-H vs. MSS + MSI-L) | 0.33 | (0.106–1.008) | 0.052 | 0.76 | (0.283–2.026) | 0.580 |
Performance status | ||||||
 (PS ≥1 vs. PS = 0) | 2.56 | (1.601–4.102) | <0.001 | 1.12 | (0.718–1.752) | 0.615 |